What the research says about Melanotan I (afamelanotide)

What Melanotan I is

Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Synthesized in 1980, it was the first alpha-MSH analogue applied to human volunteers and was designed to be more active and more stable than the natural hormone ^[1]. It binds the melanocortin-1 receptor (MC1R); MC1R signaling increases melanin synthesis, induces antioxidant activity, enhances DNA-repair processes, and modulates inflammation ^[1]. The same molecule, developed as a controlled-release subcutaneous implant, is the approved drug afamelanotide, marketed as Scenesse ^[3].

It is important to separate two things that share one molecule. Afamelanotide is a tested, approved medicine for a narrow indication. "Melanotan I" sold online as a tanning agent is the unregulated form of the same peptide. Material sold by research-chemical vendors is not the approved pharmaceutical implant and is offered for laboratory and research use only.

What the human research has measured

The controlled human evidence concerns erythropoietic protoporphyria (EPP), an inherited disorder in which accumulated protoporphyrin causes excruciating pain after light exposure and a markedly reduced quality of life ^[2][4]. Two multicenter, randomized, double-blind, placebo-controlled trials, conducted in the European Union (74 patients) and the United States (94 patients), evaluated subcutaneous afamelanotide implants against placebo to reduce pain and improve quality of life ^[2]. A phase 3 trial (CUV039) reported that afamelanotide improved light tolerance, letting patients spend more time in direct sunlight without pain and lengthening the time to onset of phototoxic symptoms compared with placebo ^[3].

On the basis of this program, afamelanotide became a first-in-class melanocortin-1-receptor agonist approved in the EU, and later the USA, for the prevention of phototoxicity in adults with EPP; reviews describe it as the first effective approved medical treatment for the condition ^[3][4]. Its pharmacology, pharmacokinetics, and post-marketing surveillance have been summarized in that indication ^[4].

By contrast, the popular cosmetic-tanning use of Melanotan I has no comparable controlled-trial base. What exists is descriptive: an anonymous online-forum survey characterized why people buy and inject illicit melanotan and how they obtain it, rather than testing safety or efficacy ^[7]. One laboratory study using keratinocytes derived from Hailey-Hailey disease lesions examined afamelanotide's antioxidant effects on cells; although it is indexed as a human clinical-trial record, the work itself is in-vitro cell research, not a clinical trial in people ^[9].

What the studies report on safety and adverse events

Reviews of afamelanotide in EPP summarize its safety and tolerability in the approved implant form and note that, as a peptide drug given repeatedly over long periods, it can raise the question of anti-drug antibodies; a dedicated assay study was developed specifically to monitor antibodies against afamelanotide and against alpha-MSH ^[4][8]. A therapeutic review covering the pharmacology and adverse-effect profile of afamelanotide in protoporphyria concluded the drug addresses a serious unmet need in that rare disease ^[5].

The safety picture for the unregulated tanning use is treated separately and less reassuringly. A dermatology review of the risks of unregulated melanotan I and II notes that, although afamelanotide itself has been thoroughly tested and deemed safe within its approved use, the illicit "melanotans" are likely risky because of unknowns in their preparation, administration, and dosage ^[6]. In other words, the safety data attach to the regulated implant, not to material bought online.

None of this is a safety guarantee or a prediction for any individual. Material sold by research-chemical vendors is not the approved product, may be impure or mislabeled, and has not passed the controlled evaluation an approved drug requires. This is not medical advice; consult a qualified professional and read the studies directly.

How strong is the evidence

The evidence is characterized as moderate, and the characterization depends entirely on which use is meant. For preventing phototoxicity in EPP, afamelanotide rests on randomized, placebo-controlled trials and regulatory approval, which within that narrow indication is genuinely robust ^[2][3][4]. For the cosmetic tanning that drives most consumer interest in "Melanotan I," there is essentially no controlled human efficacy or safety evidence, only descriptive survey and market data ^[6][7]. "Moderate" reflects that split: strong trials exist, but for a rare medical condition, not for the popular use.

Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.